Exercise in a Pill? SLU-PP-332, MOTS-c and 5-Amino-1MQ, Honestly Examined

Imagine a pill you could swallow on the sofa that would leave your muscles thinking you had just run ten kilometres — mitochondria multiplying, fat-burning genes switching on, the whole physiology of a workout, minus the sweat. It sounds like a supplement-aisle fantasy, and for the most part it still is. Yet the idea has a serious scientific pedigree. In laboratories from St Louis to Los Angeles, researchers have found real molecules that, in mice, reproduce surprising slices of what exercise does to the body. The field calls them exercise mimetics, and three of them — SLU-PP-332, MOTS-c and 5-Amino-1MQ — have escaped the journals to become some of the most talked-about compounds in longevity circles. The honest story is more interesting, and more sobering, than the marketing.

What is an exercise mimetic, really?

Exercise is not one thing your body does; it is a cascade of signals. Contracting muscle burns energy, which trips cellular fuel sensors, which in turn flip on a programme of genes that build mitochondria, shift muscle fibres toward fatigue-resistant types, and improve how the body handles sugar and fat. An exercise mimetic tries to reach into that cascade pharmacologically and pull the same levers — without the muscle ever contracting. The premise is not absurd. If a workout’s benefits are ultimately mediated by a chain of molecular messengers, then in principle a drug that mimics one of those messengers could phone in part of the response.

That is the dream. The reality is that “part of the response” is doing enormous work in that sentence, and that almost everything we know comes from animals. Three compounds illustrate the spectrum of approaches — and the spectrum of how thin the human evidence is.

How does SLU-PP-332 switch on the “endurance” gene programme?

SLU-PP-332 is the closest thing the field has to a poster child. It is a synthetic small molecule that activates the estrogen-related receptors (ERRα, β and γ), a family of nuclear receptors that sit near the top of the mitochondrial and oxidative-metabolism gene network. In the foundational study, the compound induced an ERRα-dependent “acute aerobic exercise” genetic signature and, when given to mice, increased type IIa oxidative muscle fibres and enhanced running endurance.¹ Crucially, that endurance boost depended on ERRα specifically — the activation of ERRα was critical for the effect, which is the kind of clean causal result that makes biologists pay attention.¹ A related study reported that a synthetic ERR agonist alleviated features of metabolic syndrome in obese animals,² and later medicinal-chemistry work optimised the scaffold and deepened the mechanistic picture of ERR signalling.³

It is a genuinely elegant body of work. It is also entirely rodent and cell-based. As of writing there is no published human pharmacokinetic, safety or efficacy data for SLU-PP-332 — an absence worth holding onto when you read claims about “exercise in a vial.” You can read our standalone primer on SLU-PP-332 for the molecular detail.

Is MOTS-c really an “exercise peptide”?

MOTS-c takes a different route into the same network. It is a mitochondrial-derived peptide — a short peptide encoded not in the cell’s nucleus but within the mitochondrial genome itself, a tiny signal the powerhouse sends to the rest of the cell. In mice, administering MOTS-c improves intrinsic skeletal-muscle mitochondrial bioenergetics, and it does so in a manner that depends on the master fuel sensor AMPK and the coactivator PGC-1α — the very same coactivator that physical training recruits.⁶ That is the mechanistic heart of the “exercise peptide” framing: MOTS-c plugs into the same wiring a workout uses.

MOTS-c has the most human-facing data of the three — but it is the wrong kind of data for the exercise-mimetic claim. In people, endurance training enhances skeletal-muscle mitochondrial respiration in a way linked to greater MOTS-c secretion, which is why the peptide is framed as an exercise-induced regulator.⁵ That is an association: it tells you the peptide is part of the exercise response, not that injecting it substitutes for exercise. Tellingly, when one mouse-and-human study looked directly at the human arm, it found no rise in circulating MOTS-c across muscle during acute exercise — a reminder of how unsettled even the basic human physiology remains.⁶ No controlled human intervention trial has shown MOTS-c replacing a workout. Our MOTS-c primer walks through the mitochondrial-genetics angle in full.

What does 5-Amino-1MQ actually do to metabolism?

The third compound attacks the problem from the enzyme side. 5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that consumes methyl groups and influences cellular energy balance in fat tissue. The target was validated by Kraus and colleagues, who showed that knocking down NNMT in white fat and liver protected mice from diet-induced obesity by augmenting cellular energy expenditure.⁷ Neelakantan and colleagues then translated that genetic finding into a drug, demonstrating that a selective, membrane-permeable small-molecule NNMT inhibitor reversed high-fat-diet-induced obesity in mice.⁸ Calling it an “exercise mimetic” is a stretch even by the field’s loose standards — it is really an anti-obesity metabolic tool — but it shares the same conceit: a molecule nudging energy balance in the direction a workout would. The mechanism is covered in our 5-Amino-1MQ primer.

How do the three mechanisms compare?

Strip away the branding and the three compounds are doing genuinely different things, united only by a destination — the oxidative-metabolism gene programme — and by how early they sit on the translational road.

Three routes to the same gene network — ERR agonism, a mitochondrial peptide signal, and enzyme inhibition — all still firmly at the mouse stage for the exercise claim.

Where is the marketing getting ahead of the science?

This is where intellectual honesty earns its keep. The biology here is real and, in places, beautiful — an mtDNA-encoded peptide that tunes a muscle’s mitochondria through the same machinery as training is a remarkable finding.⁶ But “remarkable in mice” and “works in humans” are separated by a graveyard of failed translations, and the exercise-mimetic field has not yet crossed it. The leap from a rodent that runs further to a person who skips the gym is exactly the kind of leap that the history of metabolic drug development has repeatedly punished.

There is also a specific safety flag worth naming. The estrogen-related receptors that SLU-PP-332 activates are not only metabolic switches; ERRα signalling is also implicated in cancer biology, where its metabolic role has seen it act as a negative prognostic marker across several tumour types.⁴ A molecule that broadly stimulates this pathway is therefore not a free lunch, and the absence of any human safety data makes that caveat more than academic. MOTS-c’s human evidence, meanwhile, is genuinely interesting but consistently correlational — the peptide tracks with the exercise response, which is not the same as the peptide replacing exercise.⁵ The pattern repeats across the category: strong mechanism, compelling mouse data, and a marketing apparatus that has sprinted past a clinic the molecules have barely entered. For the broader context of where these sit among other metabolic and longevity compounds, our NAD+ human-evidence editorial applies the same standard.

So what should a researcher take away?

The verdict is a tidy paradox: promising biology, mouse-stage reality. SLU-PP-332, MOTS-c and 5-Amino-1MQ are legitimate, well-characterised research tools that have taught us real things about how exercise rewires metabolism. They are also, every one of them, preclinical for the headline claim that gives the category its name. None has replaced a workout in a human being. The exciting science and the breathless commerce are, for now, two different stories wearing the same name.

That gap is precisely why provenance matters. These are research-use-only reference materials — not medicines, not supplements, and not approved for any human exercise, metabolic or longevity indication anywhere in the EU or US. For laboratory work, the question that determines whether an experiment means anything is not the marketing copy but the molecule in the vial: is it the compound on the label, at the stated purity, free of contaminants? Condor Research supplies each of these strictly as a research material with a Certificate of Analysis documenting identity and purity — because in a field where the biology is real but the hype is realer still, the only honest foundation is knowing exactly what you are studying.